| Diagnostic and therapeutic biomarkers in glioblastoma: current status and future perspectives W Szopa, TA Burley, G Kramer-Marek, W Kaspera BioMed research international 2017 (1), 8013575, 2017 | 352 | 2017 |
| Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging SB Lee, M Hassan, R Fisher, O Chertov, V Chernomordik, ... Clinical Cancer Research 14 (12), 3840-3849, 2008 | 196 | 2008 |
| [18F]FBEM-ZHER2:342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography G Kramer-Marek, DO Kiesewetter, L Martiniova, E Jagoda, SB Lee, ... European journal of nuclear medicine and molecular imaging 35, 1008-1018, 2008 | 176 | 2008 |
| HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents A Puri, G Kramer-Marek, R Campbell-Massa, A Yavlovich, SC Tele, ... Journal of liposome research 18 (4), 293-307, 2008 | 133 | 2008 |
| Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18F-labeled affibody molecules G Kramer-Marek, DO Kiesewetter, J Capala Journal of Nuclear Medicine 50 (7), 1131-1139, 2009 | 110 | 2009 |
| Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy M Mitsunaga, T Nakajima, K Sano, G Kramer-Marek, PL Choyke, ... BMC cancer 12, 1-8, 2012 | 108 | 2012 |
| Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters NY Morgan, G Kramer-Marek, PD Smith, K Camphausen, J Capala Radiation research 171 (2), 236-244, 2009 | 98 | 2009 |
| ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer K Feldinger, D Generali, G Kramer-Marek, M Gijsen, TB Ng, JH Wong, ... Oncotarget 5 (16), 6633, 2014 | 91 | 2014 |
| The role of nuclear medicine in modern therapy of cancer G Kramer-Marek, J Capala Tumor Biology 33, 629-640, 2012 | 79 | 2012 |
| Affitoxin—a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors R Zielinski, I Lyakhov, A Jacobs, O Chertov, G Kramer-Marek, N Francella, ... Journal of Immunotherapy 32 (8), 817-825, 2009 | 77 | 2009 |
| Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer SNM Nafi, D Generali, G Kramer-Marek, M Gijsen, C Strina, M Cappelletti, ... Oncotarget 5 (15), 5934, 2014 | 75 | 2014 |
| Spectroscopic properties and photodynamic effects of new lipophilic porphyrin derivatives: efficacy, localisation and cell death pathways G Kramer-Marek, C Serpa, A Szurko, M Widel, A Sochanik, M Snietura, ... Journal of Photochemistry and Photobiology B: Biology 84 (1), 1-14, 2006 | 75 | 2006 |
| Efficient [18F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors C Da Pieve, L Allott, CD Martins, A Vardon, DM Ciobota, G Kramer-Marek, ... Bioconjugate Chemistry 27 (8), 1839-1849, 2016 | 71 | 2016 |
| Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab EM Jagoda, L Lang, V Bhadrasetty, S Histed, M Williams, ... Journal of Nuclear Medicine 53 (10), 1592-1600, 2012 | 66 | 2012 |
| 68Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET G Kramer-Marek, N Shenoy, J Seidel, GL Griffiths, P Choyke, J Capala European journal of nuclear medicine and molecular imaging 38, 1967-1976, 2011 | 65 | 2011 |
| Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer DC Mansfield, JN Kyula, N Rosenfelder, J Chao-Chu, G Kramer-Marek, ... Gene therapy 23 (4), 357-368, 2016 | 63 | 2016 |
| Near‐infrared photoimmunotherapy targeting EGFR—Shedding new light on glioblastoma treatment TA Burley, J Mączyńska, A Shah, W Szopa, KJ Harrington, JKR Boult, ... International journal of cancer 142 (11), 2363-2374, 2018 | 58 | 2018 |
| HER2‐and EGFR‐specific affiprobes: Novel recombinant optical probes for cell imaging I Lyakhov, R Zielinski, M Kuban, G Kramer‐Marek, R Fisher, O Chertov, ... Chembiochem 11 (3), 345-350, 2010 | 58 | 2010 |
| Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89 L Allott, C Da Pieve, J Meyers, T Spinks, DM Ciobota, G Kramer-Marek, ... Chemical Communications 53 (61), 8529-8532, 2017 | 55 | 2017 |
| Near-infrared dual bioluminescence imaging in mouse models of cancer using infraluciferin CL Stowe, TA Burley, H Allan, M Vinci, G Kramer-Marek, DM Ciobota, ... Elife 8, e45801, 2019 | 54 | 2019 |
